InMed Pharmaceuticals Inc Stock Price Today (NSE: INM)
Fundamental Score
InMed Pharmaceuticals Inc Share Price — Live NSE/BSE Price, Fundamentals & Analysis
InMed Pharmaceuticals Inc share price today is ₹183.00, up +1.67% on NSE/BSE as of 31 July 2026. InMed Pharmaceuticals Inc (INM) is a Small-cap company in the Furniture, Home Furnishing sector with a market capitalisation of ₹247.57 (Cr). The 52-week high for INM share price is ₹689.00 and the 52-week low is ₹152.25. At a P/E ratio of 21.43x, INM is currently trading below its industry average P/E of 31.26x. The company has a Return on Equity (ROE) of 16.06% and a debt-to-equity ratio of 0.73.
InMed Pharmaceuticals Inc Share Price Chart — NSE/BSE Historical Performance
InMed Pharmaceuticals Inc share price chart: 4.57% return over the past month. 52-week high ₹689.00, 52-week low ₹152.25.
InMed Pharmaceuticals Inc — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹186.00 | ₹186.00 | ₹180.00 | ₹183.00 | 1.20K (Cr) | |
| ₹180.05 | ₹180.05 | ₹180.00 | ₹180.00 | 4.80K (Cr) | |
| ₹187.00 | ₹192.95 | ₹180.00 | ₹180.00 | 9.00K (Cr) | |
| ₹180.05 | ₹187.00 | ₹180.00 | ₹187.00 | 7.20K (Cr) | |
| ₹170.00 | ₹175.00 | ₹170.00 | ₹175.00 | 4.20K (Cr) | |
| ₹165.00 | ₹178.00 | ₹165.00 | ₹178.00 | 3.00K (Cr) | |
| ₹170.05 | ₹170.05 | ₹167.00 | ₹167.05 | 7.20K (Cr) | |
| ₹171.85 | ₹176.95 | ₹171.85 | ₹176.95 | 1.80K (Cr) | |
| ₹172.05 | ₹172.05 | ₹167.00 | ₹167.00 | 4.20K (Cr) | |
| ₹179.95 | ₹190.00 | ₹172.00 | ₹175.00 | 12.60K (Cr) |
InMed Pharmaceuticals Inc — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹179.95 | ₹192.95 | ₹165.00 | ₹183.00 | +1.69% | |
| ₹167.00 | ₹169.95 | ₹160.00 | ₹161.30 | -3.41% | |
| ₹155.50 | ₹191.90 | ₹152.25 | ₹183.70 | +18.14% | |
| ₹180.00 | ₹180.00 | ₹164.00 | ₹167.15 | -7.14% | |
| ₹180.00 | ₹190.00 | ₹171.00 | ₹178.25 | -0.97% | |
| ₹199.70 | ₹208.60 | ₹166.60 | ₹172.45 | -13.65% | |
| ₹249.00 | ₹250.00 | ₹182.60 | ₹195.95 | -21.31% | |
| ₹552.00 | ₹552.00 | ₹250.00 | ₹264.00 | -52.17% | |
| ₹640.00 | ₹677.00 | ₹485.10 | ₹538.45 | -15.87% | |
| ₹620.00 | ₹689.00 | ₹566.10 | ₹622.00 | +0.32% | |
| ₹558.90 | ₹633.00 | ₹550.00 | ₹620.00 | +10.93% | |
| ₹525.00 | ₹560.00 | ₹490.00 | ₹555.20 | +5.75% |
AI Research Briefing
Powered by Gemini · 2026-04-09
InMed is a binary bet on regulatory success with a looming delisting risk, making it too speculative for serious capital.
WHAT'S HAPPENING NOW (last 2-4 weeks)
InMed Pharmaceuticals received a Nasdaq notification on March 27, 2026, because its share price remained below $1.00 for 30 consecutive trading days. To regain compliance, the share price must meet or exceed $1.00 for at least 10 consecutive business days within a 180-day period. On March 23, 2026, InMed announced positive data from human brain organoid neuroinflammation models supporting their INM-901 Alzheimer's program. On March 9, 2026, the company provided a pharmaceutical development update, focusing on advancing INM-901 (Alzheimer's) and INM-089 (eye disease) towards clinical trials.
CORE STORY (THE REAL GAME)
- Upcoming pre-IND meeting with FDA for INM-901 in Q3 2026
- Positive preclinical data on INM-901 showing promise in Alzheimer's treatment
- Nasdaq compliance issues introduce near-term downside risk
- Successful pre-IND meeting with FDA
- Positive Phase 1 trial results for INM-901
- Regaining Nasdaq compliance
- Micro-cap with inherent liquidity risk
- Nasdaq delisting risk due to low share price
- Limited cash runway extending only to Q4 2026
Promoter holdings decreased by 1.72%, and FII holdings decreased by 2.73% [cite: brief]
N/A
No free cash flow reported [cite: brief]
InMed's future hinges on successful FDA interactions and clinical trial progress for INM-901. Failure to meet regulatory milestones or secure additional funding will likely lead to significant downside.
Primary Thesis Risk
Failure to regain Nasdaq compliance will trigger a collapse.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
InMed Pharmaceuticals Inc Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
InMed Pharmaceuticals Inc Fundamental Analysis & Valuation Benchmarking
Educational evaluation of INM across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (16.06%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (15.97%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (28.54%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 21.43 vs Industry: 31.26)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (40.44%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (54.37%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (63.56% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (58.57% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (110.42% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Interest Coverage (8.01x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (69.47%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Negative Free Cash Flow (₹-73.43 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 4.40%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
InMed Pharmaceuticals Inc vs Furniture, Home Furnishing Peers
Peer Comparison - Furniture, Home Furnishing
Compare InMed Pharmaceuticals Inc with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
72.2/100 | ₹183.00₹183 | ₹247.57₹247.57 | 21.43Average 21.4 Average | 16.06%Good 16.06% Good | 15.97%Good 15.97% Good | 0.73Good 0.7 Good | 110.42%Excellent 110.42% Excellent | 63.56%Excellent 63.56% Excellent | 0.28% | |
Sheela Foam LtdSheela Foam Ltd... SFL • 540203 | 39.3/100 | ₹783.80₹784 | ₹8550.04₹8550.04 | 56.78Average 56.8 Average | 4.80%Poor 4.80% Poor | 6.11%Poor 6.11% Poor | 0.28Excellent 0.3 Excellent | -7.72%Poor -7.72% Poor | 9.41%Good 9.41% Good | 0.13% |
Responsive Industries LtdResponsive Indu... RESPONIND • 505509 | 40.9/100 | ₹171.60₹172 | ₹5078.03₹5078.03 | 34.09Average 34.1 Average | 10.26%Average 10.26% Average | 10.77%Average 10.77% Average | 0.13Excellent 0.1 Excellent | 13.08%Good 13.08% Good | 13.03%Good 13.03% Good | 0.05% |
Euro Pratik SaleEuro Pratik Sal... EUROPRATIK • 544519 | 47.8/100 | ₹305.05₹305 | ₹3117.63₹3117.63 | 37.59Average 37.6 Average | 30.49%Excellent 30.49% Excellent | 38.38%Excellent 38.38% Excellent | 0.08Excellent 0.1 Excellent | — — | — — | 0.07% |
SAFEENTPSMSAFEENTPSM... SAFEENTP • | 54/100 | ₹247.50₹248 | ₹1266.71₹1266.71 | 19.61Average 19.6 Average | 35.90%Excellent 35.90% Excellent | 47.03%Excellent 47.03% Excellent | 0.00Excellent 0.0 Excellent | — — | — — | 0.00% |
BIRLANU LIMITEDBIRLANU LIMITED... BIRLANU • 509675 | 16.1/100 | ₹1334.70₹1335 | ₹947.64₹947.64 | — — | -14.86%Poor -14.86% Poor | -4.29%Poor -4.29% Poor | 1.00Good 1.0 Good | — — | 4.15%Average 4.15% Average | 1.19% |
Stanley Lifestyles LtdStanley Lifesty... STANLEY • 544202 | 37/100 | ₹157.03₹157 | ₹892.40₹892.40 | 62.34Average 62.3 Average | 3.08%Poor 3.08% Poor | 6.43%Poor 6.43% Poor | 0.66Good 0.7 Good | 58.47%Excellent 58.47% Excellent | 16.45%Excellent 16.45% Excellent | 0.00% |
27.8/100 | ₹721.00₹721 | ₹806.00₹806.00 | 123.91Average 123.9 Average | 9.36%Poor 9.36% Poor | 10.82%Average 10.82% Average | 1.21Average 1.2 Average | 7.22%Good 7.22% Good | 24.17%Excellent 24.17% Excellent | 0.03% | |
Hardwyn India LtdHardwyn India L... HARDWYN • 541276 | 61.9/100 | ₹11.27₹11 | ₹760.88₹760.88 | 59.86Average 59.9 Average | 3.18%Poor 3.18% Poor | 4.70%Poor 4.70% Poor | 0.02Excellent 0.0 Excellent | 52.52%Excellent 52.52% Excellent | 22.76%Excellent 22.76% Excellent | 0.00% |
TRANSTEEL SEATINGTRANSTEEL SEATI... TRANSTEEL • | 75.4/100 | ₹120.20₹120 | ₹271.08₹271.08 | 12.16Average 12.2 Average | 19.05%Good 19.05% Good | 21.02%Excellent 21.02% Excellent | 0.27Excellent 0.3 Excellent | 307.02%Excellent 307.02% Excellent | 43.63%Excellent 43.63% Excellent | 0.00% |
53.2/100 | ₹57.15₹57 | ₹141.77₹141.77 | 11.22Average 11.2 Average | 14.51%Average 14.51% Average | 16.96%Good 16.96% Good | 0.35Excellent 0.3 Excellent | 76.71%Excellent 76.71% Excellent | 56.70%Excellent 56.70% Excellent | 0.00% | |
Top Furniture, Home Furnishing Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sheela Foam Ltd share price8550.04 Cr
- Responsive Industries Ltd share price5078.03 Cr
- Euro Pratik Sale share price3117.63 Cr
- SAFEENTPSM share price1266.71 Cr
- BIRLANU LIMITED share price947.64 Cr
InMed Pharmaceuticals Inc Quarterly Performance
Latest quarterly metrics for INM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
54.37%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
40.44%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
63.56%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
110.42%
Compounded annual net profit growth over 5 years
InMed Pharmaceuticals Inc Technical Indicators
SMA 50, SMA 200, RSI and volume signals for INM — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
InMed Pharmaceuticals Inc Financial Statements
Annual income statement, balance sheet and cash flow for InMed Pharmaceuticals Inc (INM) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for InMed Pharmaceuticals Inc
About INM (InMed Pharmaceuticals Inc)
InMed Pharmaceuticals Inc (INM) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Furniture, Home Furnishing sect...or with a current market capitalisation of ₹247.57 (Cr). InMed Pharmaceuticals Inc has delivered a Return on Equity (ROE) of 16.06% and a ROCE of 15.97%. The debt-to-equity ratio stands at 0.73, reflecting the company's capital structure. Investors tracking INM share price can monitor key metrics including P/E ratio, promoter holding of 69.47%, and quarterly earnings growth.
Company Details
INM Share Price: Frequently Asked Questions
What is the current share price of InMed Pharmaceuticals Inc?
InMed Pharmaceuticals Inc (INM) trades at ₹183.00 on NSE. Market cap ₹247.57 (Cr). Educational data only.
What is the P/E ratio of InMed Pharmaceuticals Inc?
InMed Pharmaceuticals Inc has a P/E of 21.43x vs industry average 31.26x.
What is the Bull Run score for InMed Pharmaceuticals Inc?
InMed Pharmaceuticals Inc has a Bull Run score of 72.2/100 based on 25+ financial parameters.
Does InMed Pharmaceuticals Inc pay dividends?
InMed Pharmaceuticals Inc has a dividend yield of 0.28%. Past dividends don't guarantee future payments.
What is the ROE of InMed Pharmaceuticals Inc?
InMed Pharmaceuticals Inc has ROE of 16.06%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of InMed Pharmaceuticals Inc?
InMed Pharmaceuticals Inc has debt-to-equity of 0.73.
Is InMed Pharmaceuticals Inc a good investment?
Bull Run gives InMed Pharmaceuticals Inc a score of 72.2/100. This is not investment advice — consult a SEBI-registered advisor.